SEC Form 4 · accession 0001209191-16-119301
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curtis Ruegg
Officer — EVP, Technical Operations
Period of report
May 9, 2016
Accepted (ET)
May 11, 2016 · 6:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 9, 2016 | M | 1,000 | $8.70 | A | 26,264 | D | |
| Common Stock | May 9, 2016 | S | 1,000 | $16.18 | D | 25,264 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $8.70 | May 9, 2016 | M | 1,000 | D | — | May 26, 2023 | Common Stock | 1,000 | 49,836 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Ruegg on March 16, 2015.
- F2The shares subject to this Option vest in 48 equal monthly installments over 4 years following May 27, 2013.